About
Vironexis develops an in vivo protein engineering platform using non-integrating AAV gene therapy vectors to enable continuous, sustained expression of T-cell engagers for the treatment of cancers and immune disorders.
Explore Vironexis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.